NCT03648697
|
Adoptive T-cell immunotherapy |
LMP1, LMP2, and EBNA1-TCR-T cells |
1 dose, i.v. |
NPC |
Adverse events, clinical |
pending |
Recruiting |
NCT03925896
|
Adoptive T-cell immunotherapy |
LMP2 specific TCR-T cells |
1 dose, i.v. |
NPC |
Maximum Tolerated Dose |
pending |
Recruiting |
NCT00430534
|
Adoptive T-cell immunotherapy |
gemcitabine-carboplatin followed by EBV-specific CTL |
Multiple doses gemcitabine-carboplatin, Followed by 4 doses of EBV-specific CTL |
NPC |
Survival, disease progression |
pending |
Active (Phase III) |
NCT01498484
|
Adoptive T-cell immunotherapy |
EBV specific CTLs from HLA matched donor (ATA129) |
3 doses, i.v. |
lymphoma |
Clinical response rate |
Complete or partial remission in over 58% |
Completed (Phase II; Prockop, 2020) |
NCT03283826
|
Adoptive T-cell immunotherapy |
EBV specific CTLs from HLA matched donor (ATA129) |
3 doses, i.v. |
MS |
Adverse events, clinical progression (EDSS), MRI, IgG Index |
pending |
Recruiting |